{"protocolSection":{"identificationModule":{"nctId":"NCT01527383","orgStudyIdInfo":{"id":"V212-009"},"secondaryIdInfos":[{"id":"V212-009","type":"OTHER","domain":"Merck Protocol Number"},{"id":"2011-002313-11","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)","officialTitle":"A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients With Autoimmune Disease"},"statusModule":{"statusVerifiedDate":"2019-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-02-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2013-02-26","type":"ACTUAL"},"completionDateStruct":{"date":"2013-02-26","type":"ACTUAL"},"studyFirstSubmitDate":"2012-01-16","studyFirstSubmitQcDate":"2012-02-02","studyFirstPostDateStruct":{"date":"2012-02-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-12-03","resultsFirstSubmitQcDate":"2019-01-10","resultsFirstPostDateStruct":{"date":"2019-01-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-01-10","lastUpdatePostDateStruct":{"date":"2019-01-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is a study to evaluate the safety and immunogenicity of V212 vaccine in adults with autoimmune disease, including participants with rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis, and other similar diseases. The primary hypothesis is that vaccination with V212 vaccine will elicit significant VZV-specific immune responses at approximately 28 days after vaccination 4. The statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is \\>1.0."},"conditionsModule":{"conditions":["Herpes Zoster"],"keywords":["Shingles"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":354,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"V212","type":"EXPERIMENTAL","description":"Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.","interventionNames":["Biological: V212"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants receive placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"V212","description":"V212 viral antigen for HZ","armGroupLabels":["V212"],"otherNames":["Inactivated Varicella-Zoster (VZV) vaccine"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Placebo comparator to V212 vaccine","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA)","description":"Serum samples were tested for antibody response using a gpELISA. The GMFR is response at approximately 28 days postdose 4 / response predose on Day 1.","timeFrame":"Baseline and ~28 days after Vaccination 4 (~Day 118)"},{"measure":"GMFR in VZV Antibody Response Measured by VZV Interferon-gamma (IFN-g) Enzyme-linked Immunospot (ELISPOT) Assay","description":"Serum samples were tested for activity using a VZV ELISPOT assay. The assay detects IFN-γ-secreting, VZV-specific cells from peripheral blood mononuclear cells (PBMCs). The unit of measure of the assay is ELISPOT cell count / 10\\^6 PBMCs, and is expressed as geometric mean count (GMC). The GMFR is GMC at \\~28 days after Vaccination 4 / GMC predose on Day 1.","timeFrame":"Baseline and ~28 days after Vaccination 4 (~Day 118)"},{"measure":"Percentage of Participants With a Serious Adverse Event","description":"A serious adverse event (SAE) is defined as an adverse event that resulted in death, was life threatening, resulted in persistent or significant disability or incapacity, resulted in or prolonged a hospitalization, is a congenital anomaly or birth defect, is a cancer, was an overdose, or was an important medical event based on appropriate medical judgment. The percentage of participants with one or more SAE was assessed.","timeFrame":"Up to ~28 days after Vaccination 4 (~Day 118)"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With an Injection-site Adverse Event Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Vaccination Report Card (VRC)-prompted injection-site AEs were erythema, pain, and swelling. The percentage of participants with one or more VRC-prompted injection-site AE was assessed.","timeFrame":"Up to Day 5 after any vaccination"},{"measure":"Percentage of Participants With a Systemic Adverse Event Prompted on the Vaccination Report Card","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. VRC-prompted systemic AEs included non-injection-site varicella-like and HZ-like rashes. The percentage of participants with one or more VRC-prompted systemic AE was assessed.","timeFrame":"Up to ~28 days after Vaccination 4 (~Day 118)"},{"measure":"Percentage of Participants With Elevated Temperature Prompted on the Vaccination Report Card","description":"Elevated temperature is defined as ≥100.4 °F (≥38.0 °C), oral equivalent. The percentage of participants with VRC-prompted elevated temperature was assessed.","timeFrame":"Up to ~28 days after Vaccination 4 (~Day 118)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with an autoimmune disease\n* Clinically stable disease for at least 30 days before enrollment\n* Not likely to undergo hematopoietic stem cell transplantation during the study period\n* Receiving at least one parenteral or oral biologic agent, such as a Tumor Necrosis factor (TNF) alpha inhibitor, or a parenteral or oral non-biologic therapy, at a stable dose for at least 3 months, with no planned or anticipated changes\n* History of varicella, antibodies to VZV, or residence for at least 30 years in a country with endemic VZV infection, or if participant is less than 30 years old, attended primary or secondary school in a country with endemic VZV infection\n\nExclusion Criteria:\n\n* Prior history of Herpes Zoster (shingles) within 1 year before enrollment\n* Prior varicella or zoster vaccine\n* Active central nervous system lupus erythematosus requiring therapeutic intervention within 90 days of enrollment\n* Prior or planned therapy containing rituximab or other anti-Cluster of Differentiation (CD) 20 monoclonal antibodies from 3 months before enrollment through 28 days postdose 4\n* Systemic corticosteroid therapy, prednisone, or equivalent over 40 mg daily at the time of enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"29126292","type":"RESULT","citation":"Eberhardson M, Hall S, Papp KA, Sterling TM, Stek JE, Pang L, Zhao Y, Parrino J, Popmihajlov Z. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clin Infect Dis. 2017 Oct 1;65(7):1174-1182. doi: 10.1093/cid/cix484."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 362 participants were screened and 354 were enrolled.","groups":[{"id":"FG000","title":"V212","description":"Participants received V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."},{"id":"FG001","title":"Placebo","description":"Participants received placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"292"},{"groupId":"FG001","numSubjects":"62"}]},{"type":"Vaccination 1 (Day 1)","achievements":[{"groupId":"FG000","numSubjects":"291"},{"groupId":"FG001","numSubjects":"62"}]},{"type":"Vaccination 2 (~Day 30)","achievements":[{"groupId":"FG000","numSubjects":"283"},{"groupId":"FG001","numSubjects":"61"}]},{"type":"Vaccination 3 (~Day 60)","achievements":[{"groupId":"FG000","numSubjects":"278"},{"groupId":"FG001","numSubjects":"58"}]},{"type":"Vaccination 4 (~Day 90)","achievements":[{"groupId":"FG000","numSubjects":"277"},{"groupId":"FG001","numSubjects":"58"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"277"},{"groupId":"FG001","numSubjects":"58"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Screen failure","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Participant moved","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All enrolled participants","groups":[{"id":"BG000","title":"V212","description":"Participants received V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."},{"id":"BG001","title":"Placebo","description":"Participants received placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"292"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"354"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"18 to 49 years","categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"145"}]}]},{"title":"50 to 59 years","categories":[{"measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"103"}]}]},{"title":"60 to 69 years","categories":[{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"77"}]}]},{"title":"70 to 79 years","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"26"}]}]},{"title":"80+ years","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"226"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"128"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"52"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"248"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"301"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"28"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"239"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"288"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"34"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Autoimmune Therapy Regimen: Biologic or Non-biologic","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Biologic autoimmune therapy regimen","categories":[{"measurements":[{"groupId":"BG000","value":"142"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"170"}]}]},{"title":"Non-biologic autoimmune therapy regimen","categories":[{"measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"184"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA)","description":"Serum samples were tested for antibody response using a gpELISA. The GMFR is response at approximately 28 days postdose 4 / response predose on Day 1.","populationDescription":"Participants with Day 1 and/or postdose data available. This outcome measure applied only to participants who received V212; placebo participants were not assessed for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline and ~28 days after Vaccination 4 (~Day 118)","groups":[{"id":"OG000","title":"V212","description":"Participants received V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","lowerLimit":"1.44","upperLimit":"1.72"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Longitudinal regression","statisticalComment":"Visit and stratification factor (biologic or non-biologic autoimmune therapy) were covariates","otherAnalysisDescription":"The statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is \\>1.0."}]},{"type":"PRIMARY","title":"GMFR in VZV Antibody Response Measured by VZV Interferon-gamma (IFN-g) Enzyme-linked Immunospot (ELISPOT) Assay","description":"Serum samples were tested for activity using a VZV ELISPOT assay. The assay detects IFN-γ-secreting, VZV-specific cells from peripheral blood mononuclear cells (PBMCs). The unit of measure of the assay is ELISPOT cell count / 10\\^6 PBMCs, and is expressed as geometric mean count (GMC). The GMFR is GMC at \\~28 days after Vaccination 4 / GMC predose on Day 1.","populationDescription":"Participants with Day 1 and/or postdose data available. This outcome measure applied only to participants who received V212; placebo participants were not assessed for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline and ~28 days after Vaccination 4 (~Day 118)","groups":[{"id":"OG000","title":"V212","description":"Participants received V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.01","lowerLimit":"1.57","upperLimit":"2.58"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Longitudinal regression","statisticalComment":"Visit and stratification factor (biologic or non-biologic autoimmune therapy) were covariates","otherAnalysisDescription":"The statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is \\>1.0."}]},{"type":"PRIMARY","title":"Percentage of Participants With a Serious Adverse Event","description":"A serious adverse event (SAE) is defined as an adverse event that resulted in death, was life threatening, resulted in persistent or significant disability or incapacity, resulted in or prolonged a hospitalization, is a congenital anomaly or birth defect, is a cancer, was an overdose, or was an important medical event based on appropriate medical judgment. The percentage of participants with one or more SAE was assessed.","populationDescription":"All participants who received at least one dose of vaccine and had safety follow-up","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to ~28 days after Vaccination 4 (~Day 118)","groups":[{"id":"OG000","title":"V212","description":"Participants received V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."},{"id":"OG001","title":"Placebo","description":"Participants received placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"},{"groupId":"OG001","value":"1.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Injection-site Adverse Event Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Vaccination Report Card (VRC)-prompted injection-site AEs were erythema, pain, and swelling. The percentage of participants with one or more VRC-prompted injection-site AE was assessed.","populationDescription":"All participants who received at least one dose of vaccine and had safety follow-up","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to Day 5 after any vaccination","groups":[{"id":"OG000","title":"V212","description":"Participants received V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."},{"id":"OG001","title":"Placebo","description":"Participants received placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"62"}]}],"classes":[{"title":"Injection-site erythema","categories":[{"measurements":[{"groupId":"OG000","value":"46.0"},{"groupId":"OG001","value":"1.6"}]}]},{"title":"Injection-site pain","categories":[{"measurements":[{"groupId":"OG000","value":"42.2"},{"groupId":"OG001","value":"14.5"}]}]},{"title":"Injection-site swelling","categories":[{"measurements":[{"groupId":"OG000","value":"40.1"},{"groupId":"OG001","value":"4.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Systemic Adverse Event Prompted on the Vaccination Report Card","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. VRC-prompted systemic AEs included non-injection-site varicella-like and HZ-like rashes. The percentage of participants with one or more VRC-prompted systemic AE was assessed.","populationDescription":"All participants who received at least one dose of vaccine and had safety follow-up","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to ~28 days after Vaccination 4 (~Day 118)","groups":[{"id":"OG000","title":"V212","description":"Participants received V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."},{"id":"OG001","title":"Placebo","description":"Participants received placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6"},{"groupId":"OG001","value":"46.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Elevated Temperature Prompted on the Vaccination Report Card","description":"Elevated temperature is defined as ≥100.4 °F (≥38.0 °C), oral equivalent. The percentage of participants with VRC-prompted elevated temperature was assessed.","populationDescription":"All participants who received at least one dose of vaccine and had safety follow-up","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to ~28 days after Vaccination 4 (~Day 118)","groups":[{"id":"OG000","title":"V212","description":"Participants received V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."},{"id":"OG001","title":"Placebo","description":"Participants received placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0"},{"groupId":"OG001","value":"4.9"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to Day 140","description":"All participants who received at least one dose of vaccine and had safety follow-up","eventGroups":[{"id":"EG000","title":"V212","description":"Participants received V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.","deathsNumAffected":1,"deathsNumAtRisk":289,"seriousNumAffected":9,"seriousNumAtRisk":289,"otherNumAffected":171,"otherNumAtRisk":289},{"id":"EG001","title":"Placebo","description":"Participants received placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.","deathsNumAffected":0,"deathsNumAtRisk":62,"seriousNumAffected":1,"seriousNumAtRisk":62,"otherNumAffected":11,"otherNumAtRisk":62}],"seriousEvents":[{"term":"Anaemia haemolytic autoimmune","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Diffuse large B-cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]}],"otherEvents":[{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":318,"numAffected":133,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":270,"numAffected":122,"numAtRisk":289},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":62}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":24,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":255,"numAffected":116,"numAtRisk":289},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":62}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":21,"numAtRisk":289},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":62}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Australia","Canada","Colombia","Denmark","Estonia","Israel","Netherlands","Peru","Spain","Sweden","United States"]},"conditionBrowseModule":{"meshes":[{"id":"D006562","term":"Herpes Zoster"}],"ancestors":[{"id":"D000073618","term":"Varicella Zoster Virus Infection"},{"id":"D006566","term":"Herpesviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"D014612","term":"Vaccines"}],"ancestors":[{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}